Obesity and metabolic syndrome, with increased risk of eventual cardiovascular disease
and type II diabetes, are significant problems for patients receiving antipsychotic drugs and …

Although weight gain is a serious but variable adverse effect of antipsychotics that has
genetic underpinnings, a comprehensive meta-analysis of pharmacogenetics of …

Abstract Second-generation antipsychotics (SGAs), such as risperidone, clozapine and
olanzapine, are the most common drug treatments for schizophrenia. SGAs presented an …

Antipsychotic medications are critical to child and adolescent psychiatry, from the
stabilization of psychotic disorders like schizophrenia, bipolar disorder, and psychotic …

The last decade of research into the pharmacogenetics of antipsychotics has seen the
development of genetic tests to determine the patients' metabolic status and the first attempts …

Metabolic syndrome (MetS) is a cluster of factors that increases the risk of cardiovascular
disease (CVD), one of the leading causes of mortality in patients with schizophrenia …

Objective: During the past decades, increasing efforts have been invested in studies to
unravel the influence of genetic factors on antipsychotic (AP) dosage, treatment response …

The human genome encodes nine different adrenoceptor genes. These are grouped into
three families, namely, the α 1-, α 2-, and β-adrenoceptors, with three family members each …

Psychiatric pharmacotherapy with olanzapine is commonplace. We investigated the
influence of CYP1A2* 1F (− 163A, rs762551) and serotonergic polymorphisms on …

Classic and modern antipsychotics can induce substantial weight gain causing diabetes,
lipid abnormalities and psychological distress. Treatment emergent weight gain varies within …